Vascular Inflammation Imaging in Psoriasis

AbstractPurpose of ReviewPsoriasis is a common, chronic inflammatory skin disease driven by immune dysregulation involving helper T cell 17 pathways. Psoriasis is associated with systemic inflammation, which increases the risk of joint disease (psoriatic arthritis), subclinical cardiovascular disease, and major adverse cardiovascular events, especially in young patients with severe skin disease. Furthermore, vascular inflammation by 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) provides a valuable tool with utility in predicting future cardiovascular events. As such, psoriasis provides a clinical human model to characterize the vascular disease by non-invasive imaging techniques such as vascular inflammation by FDG PET/CT.Recent FindingsFDG PET/CT has garnered considerable interest in multiple completed and ongoing cardiovascular and psoriasis trials. Indeed, recent studies have shown that psoriasis is associated with increased vascular inflammation. Furthermore, a dose-response was demonstrated between severity of skin disease and severity of vascular inflammation in psoriasis. Additionally, observational studies have reported that treatment of psoriasis decreases vascular inflammation with several randomized trials still ongoing. Emerging data from a single report demonstrated that use of FDG PET/MRI may provide soft tissue localization of the FDG tracer in the aorta and the carotids but larger studies are underway.SummaryThis review ou...
Source: Current Cardiovascular Imaging Reports - Category: Radiology Source Type: research

Related Links:

Abstract Psoriasis affects 1-3% of the population and up to 1/3 of psoriasis patients have underlying psoriatic arthritis (PsA)1 . Non-specific musculoskeletal complaints are even higher, being around 50%2 . Detecting early signs of PsA and early treatments are crucial to improve the outcomes to prevent progressive, damaging arthritis3 . Due to the high frequency of non-specific pain in psoriasis, it is not possible for every psoriasis patient with joint pain to be assessed by a rheumatologist. PMID: 31505032 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
ObjectiveTo evaluate the associations of C ‐reactive protein (CRP) and circulating Th17‐associated cytokine levels with psoriatic arthritis (PsA) disease activity and therapeutic response to ustekinumab.MethodsInterleukin ‐17A (IL‐17A), IL‐17F, IL‐23, and CRP concentrations were measured in serum samples collected as part of the 2 PSUMMIT phase III studies of ustekinumab in PsA (n = 927). In post hoc analyses, relationships of IL‐17A, IL‐17F, and CRP levels at baseline, week 4, and week 24 with baseline s kin and joint disease activity and response to therapy were evaluated using generalized linear models a...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
Psoriasis developed through abnormal crosstalk between the immune cells and epidermal keratinocytes. Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor and has been approved for the treatment of patients with plaque psoriasis and psoriatic arthritis. Cyclic adenosine monophosphate (cAMP) has a significant role as a secondary messenger and PDE4 degrades intercellular cAMP to AMP. It is widely recognized that PDE4 inhibition by Apremilast increases intracellular cAMP levels in immune cells, thereby in turn suppress the expression of proinflammatory cytokines, such as TNF- α, IFN-γ and IL-23, which are all...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Innate Immunity and Inflammation Source Type: research
We are performing omic analyses of psoriasis and psoriatic arthritis (PsA) patients to address the hypothesis that biomarker discovery will inform more individualized care of individuals (endotypes) with psoriasis and their comorbidities. We collected whole blood from psoriasis patients (n=59, 16 PsA; mean PASI=8.6 (range 0-33.5) with 9 healthy controls) and PBMCs (n=9 psoriasis, n=5 controls). RNASeq was performed using Illumina TruSeq Total RNA kits and a NextSeq 550 (15M+ paired reads/sample, 75 bp).
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research and Epidemiology Source Type: research
Ustekinumab, a monoclonal antibody that targets interleukin (IL)-12/23, is used to treat psoriasis, psoriatic arthritis and Crohn disease. In 2011, a meta-analysis of randomized trials alerted on a potential risk of major adverse cardiovascular events (MACE) within the first months after the initiation of anti-IL-12/23 antibodies. Our objective was to assess if ustekinumab initiation may trigger MACE. Using the French National Health Insurance database, covering 66 million subjects, we included all patients exposed to ustekinumab between 2010 and 2016, classified according to their cardiovascular risk level (high vs.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research and Epidemiology Source Type: research
The objective of this study was to explore whether plasma-derived EV microRNAs may serve as biomarkers for PsA in patients with psoriasis.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Innate Immunity and Inflammation Source Type: research
Conclusions: Serum lipocalin-2 concentrations are higher in psoriasis/PsA patients than controls. However, more large-scale studies are warranted to explore the association between serum lipocalin-2 and the pathogenetic mechanisms of psoriasis/PsA. PMID: 31467617 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
CONCLUSION: (1) Both immune disorder and bone metabolic dysregulation could be the shared mechanism in the development of PsA, PV, RA, and GA. (2) Immune dysfunction is involved in GA. Our study may shed new light on the diagnosis and treatment strategy of these autoimmune diseases and GA, which warrants further studies. PMID: 31465725 [PubMed - in process]
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research
The interleukin-17A inhibitor is now indicated for the treatment of adults with active ankylosing spondylitis, as well as for certain patients with plaque psoriasis and active psoriatic arthritis.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
Innovative Therapy Will Strengthen Amgen's Inflammation Portfolio for Patients Around the World Acquisition Expected to Accelerate Growth and Enhance Value for Amgen Shareholders Amgen to Host Call With Investors at 5 a.m. PT (8 a.m. ET) THOUSAND ... Biopharmaceuticals, Acquisitions Amgen, Celgene, Otezla, apremilast, psoriasis, psoriatic arthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Arthritis | Cardiology | Cardiovascular | CT Scan | Heart | PET Scan | Psoriasis | Psoriatic Arthritis | Radiology | Rheumatology | Skin | Study